维普中文期刊产品整合服务
81篇 您的检索式:作者名="CLOUD J"
    题名 作者 年代 出处 被引量
1Comparison of six methods of extracting mycobacterium tuberculosis DNA from processed sputum for testing by quantitative real time PCR显示文摘Aldous W K Pounder J I Cloud J L 2005J Clin Microbiol2005,43,5:1
2Comparison of traditional phenotypie identification methods with partial 5'16S rRNA gene sequencing for species-level identification of nonfermenting gram- negative bacilli显示文摘Cloud J L Harmsen D Iwenet P C 2010J Clin Microbiol2010,48,4:1
3Introduction to Interval Analysis显示文摘Moore R E Kearfott R B Cloud M J 2009Society for Industrial and Applied Mathematics2009,,269:1
4Unconfined deflagrative explosions without turbulence显示文摘Leyer J C Desbordes D Saint Cloud J P 1993Journal of Hazardous Materials1993,34,:1
5Evaluation of matrix-assisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria 显示文摘Mellmann A Cloud J Maier T 2008J Clin Microbiol2008,46,6:1
6Evaluation of matrixassisted laser desorption ionization-time-of-flight mass spectrometry in comparison to 16S rRNA gene sequencing for species identification of nonfermenting bacteria显示文摘MELLMANN A CLOUD J MAIER T 2008J Clin Microbiol2008,46,6:1
7In vitro and in vivo characterization of avian Escherichia coli II factors associated with pathogenicity 显示文摘Rosenberger J K Fries P A Cloud S S 1985Avian Dis1985,29,:1
8queuing systems 显示文摘Khazaei H Misic J Misic V: Performance analysis of cloud computing centers using M/G/m/m+r 2012IEEE Trans Parallel Distributed Syst2012,23,:1
9Evaluation of matrixassisted laser desorption ionization-time-of-flight mass spectrometry incomparison to 16SrRNA gene sequencing for species identification of nonfermentingbacteria显示文摘Mellmann A Cloud J Maier T 2008J Clin Microbiol2008,46,6:1
10In vitro and in vivo characterization of avian Escherichia coli Ⅱ factors associated with pathogenicity显示文摘Rosenberger J K Fries P A Cloud S S 1985Avian Dis1985,29,:1
11Immune dysfunciton folliwing infection with chicken anemia agent and infectious bursal disease virus,I, Kinetic alteratons of avian lymphocyte Subpopulations, Veterinary 显示文摘Cloud S S Liluehoj H S Rosenberger J K 1992Immunology and Immunopathology1992,34,:1
12The isolation and charac- terization of chicken an emiaagent(CAA)From broilers in the United States显示文摘Rosenberger J K Cloud S S 1989Avian Dis1989,33,:1
13Cryptococcosis in human immunodeficiency virus-negative patients in the era of ef- fective azole therapy 显示文摘Pappas P G Perfect J R Cloud G A 2001Clin Infect Dis2001,33,5:1
14Double blind placebo- controlled trial of pleconaril in infants with enterovirus menin- giti显示文摘Abzug MJ Cloud G Bradley J 2003Pediatrlnfect Dis J2003,22,33:1
15Update on clostridium difficile associated disease 显示文摘Cloud J Kelly CP 2007Curr Opin Gastroenterol2007,23,:1
16Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments.Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis 2022Stroke & Vascular Neurology2022,7,2:1
17A method for measuring the adhesion strength of marine mussels显示文摘BURKETT J R WOJTAS J L CLOUD J L 2009Journal of Adhesion2009,85,:1
18Detection of Le gionella species in respiratory specimens using PCR with sequencing confirmation显示文摘Cloud J L K C Carroll P Pixton 2000Journal of Clinical Microbiology2000,38,5:1
19Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital eytomegalovirus infections involving the central nervous system显示文摘Oliver SE Cloud GA S/mchez P J 2009J Clin Virol2009,464,:1
20Rapid species identification within the Mycobacterium chelonae-abscessus group by high-resolution melting analysis of hsp65 PCR products显示文摘ODELL I D CLOUD J L SEIPP M 2005Am J Clin Pathol2005,123,:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费